TY - JOUR
T1 - High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction
AU - Li, Gang
AU - Martínez-Bonet, Marta
AU - Wu, Di
AU - Yang, Yu
AU - Cui, Jing
AU - Nguyen, Hung N.
AU - Cunin, Pierre
AU - Levescot, Anaïs
AU - Bai, Ming
AU - Westra, Harm Jan
AU - Okada, Yukinori
AU - Brenner, Michael B.
AU - Raychaudhuri, Soumya
AU - Hendrickson, Eric A.
AU - Maas, Richard L.
AU - Nigrovic, Peter A.
N1 - Funding Information:
We thank P. Y. Lee, I-C. Ho, P. Libby and R. M. Plenge for scientific discussions. This work was supported by grants from the Arthritis National Research Foundation, National Multiple Sclerosis Society, NIH R21 NS096443 and NIH R21 AR070378 (G.L.), and from the Rheumatology Research Foundation, NIH R01 AR065538, NIH P30 AR070253 and the Fundación Bechara (P.A.N.).
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Genome-wide association studies (GWAS) have identified many disease-associated noncoding variants, but cannot distinguish functional single-nucleotide polymorphisms (fSNPs) from others that reside incidentally within risk loci. To address this challenge, we developed an unbiased high-throughput screen that employs type IIS enzymatic restriction to identify fSNPs that allelically modulate the binding of regulatory proteins. We coupled this approach, termed SNP-seq, with flanking restriction enhanced pulldown (FREP) to identify regulation of CD40 by three disease-associated fSNPs via four regulatory proteins, RBPJ, RSRC2 and FUBP-1/TRAP150. Applying this approach across 27 loci associated with juvenile idiopathic arthritis, we identified 148 candidate fSNPs, including two that regulate STAT4 via the regulatory proteins SATB2 and H1.2. Together, these findings establish the utility of tandem SNP-seq/FREP to bridge the gap between GWAS and disease mechanism.
AB - Genome-wide association studies (GWAS) have identified many disease-associated noncoding variants, but cannot distinguish functional single-nucleotide polymorphisms (fSNPs) from others that reside incidentally within risk loci. To address this challenge, we developed an unbiased high-throughput screen that employs type IIS enzymatic restriction to identify fSNPs that allelically modulate the binding of regulatory proteins. We coupled this approach, termed SNP-seq, with flanking restriction enhanced pulldown (FREP) to identify regulation of CD40 by three disease-associated fSNPs via four regulatory proteins, RBPJ, RSRC2 and FUBP-1/TRAP150. Applying this approach across 27 loci associated with juvenile idiopathic arthritis, we identified 148 candidate fSNPs, including two that regulate STAT4 via the regulatory proteins SATB2 and H1.2. Together, these findings establish the utility of tandem SNP-seq/FREP to bridge the gap between GWAS and disease mechanism.
UR - http://www.scopus.com/inward/record.url?scp=85049950726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049950726&partnerID=8YFLogxK
U2 - 10.1038/s41588-018-0159-z
DO - 10.1038/s41588-018-0159-z
M3 - Article
C2 - 30013183
AN - SCOPUS:85049950726
SN - 1061-4036
VL - 50
SP - 1180
EP - 1188
JO - Nature Genetics
JF - Nature Genetics
IS - 8
ER -